Renal arteriovenous transit times of technetium-radiolabeled chelates.
A noninvasive method was developed for quantitating the distribution of renal arteriovenous transit times of technetium-99m (99mTc) radiopharmaceuticals. Using this method, the characteristic transit times and amplitudes of the first two components of [99mTC] DTPA or MDP transit through the renal vasculature were calculated. The first component amplitude (A1) was evaluated for its ability to discriminate between 20 hypertensive patients with renovascular disease and 21 normotensive subjects. A1 was compared with three other quantitative indices: the ascending slope of the initial renal time-activity curve, the kidney-to-aorta slope ratio (K/A), and renal size. A1 nearly perfectly separated the hypertensive patients from the normotensive subjects; the ability of A1 to discriminate between these two groups is clearly superior to renal size, the initial renal slope, and K/A. We conclude that measurements of the intrarenal distribution of blood flow have distinct advantages over indices of renal blood flow that have been derived from scintillation camera measurements of 99mTc radiopharmaceuticals.
Conrad
G R
GR
Wesolowski
C A
CA
Berbaum
K S
KS
Jensen
K C
KC
Kirchner
P T
PT
D006801:Humans; D006978:Hypertension, Renovascular / Q000000981:diagnostic imaging; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011866:Radioisotope Renography / Q000379:methods*; D012079:Renal Circulation; D013669:Technetium Tc 99m Medronate; D016284:Technetium Tc 99m Pentetate
D009942:Organometallic Compounds; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate; D013669:Technetium Tc 99m Medronate